

103<sup>D</sup> CONGRESS  
2<sup>D</sup> SESSION

# S. 784

---

IN THE HOUSE OF REPRESENTATIVES

AUGUST 16, 1994

Referred to the Committee on Energy and Commerce

---

## AN ACT

To amend the Federal Food, Drug, and Cosmetic Act to establish standards with respect to dietary supplements, and for other purposes.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Dietary Supplement  
5       Health and Education Act of 1994”.

1 **SEC. 2. FINDINGS AND PURPOSE.**

2 (a) FINDINGS.—Congress finds that—

3 (1) improving the health status of United  
4 States citizens ranks at the top of the national prior-  
5 ities of the Federal Government;

6 (2) the importance of nutrition and the benefits  
7 of dietary supplements to health promotion and dis-  
8 ease prevention have been documented increasingly  
9 in scientific studies;

10 (3)(A) there is a definitive link between the in-  
11 gestion of certain nutrients or dietary supplements  
12 and the prevention of chronic diseases such as can-  
13 cer, heart disease, and osteoporosis; and

14 (B) clinical research has shown that several  
15 chronic diseases can be prevented simply with a  
16 healthful diet, such as a diet that is low in fat, satu-  
17 rated fat, cholesterol, and sodium, with a high pro-  
18 portion of plant-based foods;

19 (4) healthful diets may mitigate the need for  
20 expensive medical procedures, such as coronary by-  
21 pass surgery or angioplasty;

22 (5) preventive health measures, including edu-  
23 cation, good nutrition, and appropriate use of safe  
24 nutritional supplements will limit the incidence of  
25 chronic diseases, and reduce long-term health care  
26 expenditures;

1           (6)(A) promotion of good health and healthy  
2           lifestyles improves and extends lives while reducing  
3           health care expenditures; and

4           (B) reduction in health care expenditures is of  
5           paramount importance to the future of the country  
6           and the economic well-being of the country;

7           (7) there is a growing need for emphasis on the  
8           dissemination of information linking nutrition and  
9           long-term good health;

10          (8) consumers should be empowered to make  
11          choices about preventive health care programs based  
12          on data from scientific studies of health benefits re-  
13          lated to particular dietary supplements;

14          (9)(A) national surveys have revealed that al-  
15          most 50 percent of the 260,000,000 Americans reg-  
16          ularly consume dietary supplements of vitamins,  
17          minerals, or herbs as a means of improving their nu-  
18          trition; and

19          (B) nearly all consumers indicate that dietary  
20          supplements should not be regulated as drugs;

21          (10) studies indicate that consumers are placing  
22          increased reliance on the use of nontraditional  
23          health care providers to avoid the excessive costs of  
24          traditional medical services and to obtain more holis-  
25          tic consideration of their needs;

1           (11) the United States will spend over  
2           \$1,000,000,000,000 on health care in 1994, which is  
3           about 12 percent of the Gross National Product of  
4           the United States, and this amount and percentage  
5           will continue to increase unless significant efforts  
6           are undertaken to reverse the increase;

7           (12)(A) the nutritional supplement industry is  
8           an integral part of the economy of the United  
9           States;

10          (B) the industry consistently projects a positive  
11          trade balance; and

12          (C) the estimated 600 dietary supplement man-  
13          ufacturers in the United States produce approxi-  
14          mately 4,000 products, with total annual sales of  
15          such products alone reaching at least  
16          \$4,000,000,000;

17          (13) although the Federal Government should  
18          take swift action against products that are unsafe or  
19          adulterated, the Federal Government should not  
20          take any actions to impose regulatory barriers limit-  
21          ing or slowing the flow of safe products and needed  
22          information to consumers;

23          (14) dietary supplements are safe within a  
24          broad range of intake, and safety problems with the  
25          supplements are relatively rare; and

1           (15)(A) legislative action that protects the right  
2 of access of consumers to safe dietary supplements  
3 is necessary in order to promote wellness; and

4           (B) a rational Federal framework must be es-  
5 tablished to supersede the current ad hoc, patchwork  
6 regulatory policy on dietary supplements.

7       (b) PURPOSE.—It is the purpose of this Act to—

8           (1) improve the health status of the people of  
9 the United States and help constrain runaway health  
10 care spending by ensuring that the Federal Govern-  
11 ment erects no regulatory barriers that impede the  
12 ability of consumers to improve their nutrition  
13 through the free choice of safe dietary supplements;

14          (2) clarify that—

15           (A) dietary supplements are not drugs or  
16 food additives;

17           (B) dietary supplements should not be reg-  
18 ulated as drugs;

19           (C) regulations relating to food additives  
20 are not applicable to dietary supplements and  
21 their ingredients used for food additive pur-  
22 poses, including stabilizers, processing agents,  
23 or preservatives; and

24           (D) the burden of proof is on the Food  
25 and Drug Administration to prove that a prod-

1           uct is unsafe before it can be removed from the  
2           marketplace;

3           (3) establish a new definition of a dietary sup-  
4           plement that differentiates dietary supplements from  
5           conventional foods, while recognizing the broad  
6           range of food ingredients used to supplement the  
7           diet;

8           (4) strengthen the current enforcement author-  
9           ity of the Food and Drug Administration by provid-  
10          ing to the Administration additional mechanisms to  
11          take enforcement action against unsafe or fraudu-  
12          lent products;

13          (5) establish a series of labeling requirements  
14          that will provide consumers with greater information  
15          and assurance about the quality and content of die-  
16          tary supplements, while at the same time assuring  
17          the consumers the freedom to use the supplements  
18          of their choice;

19          (6) provide new administrative and judicial re-  
20          view procedures to affected parties if the Food and  
21          Drug Administration takes certain actions to enforce  
22          dietary supplement requirements; and

23          (7) establish a Commission on Dietary Supple-  
24          ment Labels within the executive branch to develop  
25          recommendations on a procedure to evaluate health

1 claims for dietary supplements and provide rec-  
2 ommendations to the President and the Congress.

3 **SEC. 3. DEFINITIONS.**

4 (a) DEFINITION OF CERTAIN FOODS AS DIETARY  
5 SUPPLEMENTS.—Section 201 of the Federal Food, Drug,  
6 and Cosmetic Act (21 U.S.C. 321) is amended by adding  
7 at the end the following:

8 “(ff) The term ‘dietary supplement’ means—

9 “(1) a product intended to supplement the diet  
10 by increasing the total dietary intake that bears or  
11 contains one or more of the following dietary ingre-  
12 dients:

13 “(A) a vitamin;

14 “(B) a mineral;

15 “(C) an herb or other botanical;

16 “(D) an amino acid;

17 “(E) another dietary substance for use by  
18 man to supplement the diet by increasing the  
19 total dietary intake; or

20 “(F) a concentrate, metabolite, constitu-  
21 ent, extract, or combination of any ingredient  
22 described in clause (A), (B), (C), (D), (E) or  
23 (F);

24 “(2) a product that—

1           “(A)(i) is intended for ingestion in a form  
2           described in section 411(c)(1)(B)(i); or

3           “(ii) complies with section 411(c)(1)(B)(ii);  
4           and

5           “(B) is not represented for use as a con-  
6           ventional food or as a sole item of a meal or the  
7           diet; and

8           “(C) is labeled as a dietary supplement.”.

9           (b) EXCLUSION FROM DEFINITION OF DRUG.—Sec-  
10          tion 201(g) of the Federal Food, Drug, and Cosmetic Act  
11          (21 U.S.C. 321(g)) is amended by adding at the end the  
12          following new subparagraph:

13          “(3) The term ‘drug’ does not include a dietary sup-  
14          plement as defined in paragraph (ff), except that—

15               “(A) an article that is approved as a new drug,  
16               certified as an antibiotic (under section 355 or 357),  
17               or licensed as a biologic (under section 351 of the  
18               Public Health Service Act (42 U.S.C. 262 et seq.))  
19               and was, prior to such approval, certification or li-  
20               cense, marketed as a dietary supplement or as a  
21               food, may continue to be offered for sale as a dietary  
22               supplement unless the Secretary has issued a regula-  
23               tion, after notice and comment, finding that the arti-  
24               cle when used as or in a dietary supplement under  
25               the conditions of use and dosages set forth in the la-



1       belong for such dietary supplement, is unlawful  
2       under section 402(f); and

3               “(B) an article that is approved as a new drug,  
4       certified as an antibiotic (under section 355 or 357),  
5       or licensed as a biologic (under section 351 of the  
6       Public Health Service Act (42 U.S.C. 262 et seq.))  
7       and was not prior thereto marketed as a dietary  
8       supplement or as a food, may not be considered as  
9       a dietary ingredient or dietary supplement unless the  
10      Secretary has issued a regulation, after notice and  
11      comment, finding that the article would be lawful  
12      under section 402(f) under the conditions of use and  
13      dosages set forth in the recommended labeling for  
14      such article.”.

15      (c) EXCLUSION FROM DEFINITION OF FOOD ADDI-  
16      TIVE.—Section 201(s) of the Federal Food, Drug, and  
17      Cosmetic Act (21 U.S.C. 321(s)) is amended—

18              (1) by striking “or” at the end of subparagraph  
19      (4);

20              (2) by striking the period at the end of sub-  
21      paragraph (5) and inserting “; or”; and

22              (3) by adding at the end the following new sub-  
23      paragraph:

24              “(6) an ingredient described in paragraph (ff)  
25      in, or intended for use in, a dietary supplement.”.

1 (d) FORM OF INGESTION.—Section 411(c)(1)(B) of  
2 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
3 350(c)(1)(B)) is amended—

4 (1) in clause (i), by inserting “powder, softgel,  
5 gelcap,” after “capsule,”; and

6 (2) in clause (ii), by striking “does not simulate  
7 and”.

8 **SEC. 4. SAFETY OF DIETARY SUPPLEMENTS AND BURDEN**  
9 **OF PROOF ON FDA.**

10 Section 402 of the Federal Food, Drug, and Cosmetic  
11 Act (21 U.S.C. 342) is amended by adding at the end the  
12 following:

13 “(f) If it is a dietary supplement that—

14 “(1) the Secretary finds, after rulemaking, pre-  
15 sents a substantial and unreasonable risk of illness  
16 or injury under conditions of use recommended or  
17 suggested in labeling;

18 “(2) the Secretary declares to pose an imminent  
19 and substantial hazard to public health or safety, ex-  
20 cept that the authority to make such declaration  
21 shall not be delegated and the Secretary shall  
22 promptly thereafter convene rulemaking pursuant to  
23 section 701(e), (f), and (g) to affirm or withdraw  
24 the declaration; or

1 “(3) is or contains a dietary ingredient that  
 2 renders it adulterated under paragraph (a)(1) under  
 3 the conditions of use recommended or suggested in  
 4 the labeling of such dietary supplement.

5 In any proceeding under this section, the United States  
 6 bears the burden of proof on each element to show that  
 7 a dietary supplement is adulterated.”.

8 **SEC. 5. DIETARY SUPPLEMENT CLAIMS.**

9 (a) SUPPLEMENT CLAIMS.—Chapter IV of the Fed-  
 10 eral Food, Drug, and Cosmetic Act (21 U.S.C. 341 et  
 11 seq.) is amended by inserting after section 403A the fol-  
 12 lowing new section:

13 “DIETARY SUPPLEMENT LABELING EXEMPTIONS

14 “SEC. 403B. An article, another publication, a chap-  
 15 ter in books, or the official abstract of a peer-reviewed sci-  
 16 entific publication that appears in the article and was pre-  
 17 pared by the author or the editors of the publication, re-  
 18 printed in its entirety, shall not be defined as labeling  
 19 when used in connection with the sale of dietary supple-  
 20 ments to consumers when it—

21 “(1) is not false or misleading;

22 “(2) does not promote a particular brand of a  
 23 dietary supplement;

24 “(3) is displayed or presented, or is displayed  
 25 or presented with other such items on the same sub-  
 26 ject matter, so as to present a balanced view of the

1 available scientific information on a dietary supple-  
2 ment; and

3 “(4) if displayed in an establishment, is phys-  
4 ically separate from the dietary supplements.

5 This section shall not apply to or restrict a retailer or  
6 wholesaler of dietary supplements in any way whatsoever  
7 in the sale of books or other publications as a part of the  
8 business of such retailer or wholesaler. In any proceeding  
9 under this section, the burden of proof shall be on the  
10 United States to establish that an article or other such  
11 matter is false or misleading.”.

12 **SEC. 6. STATEMENTS OF NUTRITIONAL SUPPORT.**

13 Section 403(r)(1) of the Federal Food, Drug, and  
14 Cosmetic Act (21 U.S.C. 343(r)(1)) is amended by adding  
15 the following new sentence at the end:“For purposes of  
16 this subparagraph, a statement for a dietary supplement  
17 shall not be considered a claim of the relationship of a  
18 nutrient or dietary ingredient to a disease or health-relat-  
19 ed condition if the statement does not claim to diagnose,  
20 prevent, mitigate, treat, or cure a specific disease or class  
21 of diseases. A statement for a dietary supplement may be  
22 made if the statement claims a benefit related to a classi-  
23 cal nutrient deficiency disease and discloses the prevalence  
24 of such disease in the United States, describes the role  
25 of a nutrient or dietary ingredient intended to affect the

1 structure or function in humans, characterizes the docu-  
2 mented mechanism by which a nutrient or dietary ingredi-  
3 ent acts to maintain such structure or function, or de-  
4 scribes general well-being from consumption of a nutrient  
5 or dietary ingredient.”.

6 **SEC. 7. CONFORMING AMENDMENTS.**

7 (a) SECTION 201.—The next to the last sentence of  
8 section 201(g)(1) of the Federal Food, Drug, and Cos-  
9 metic Act (21 U.S.C. 321(g)(1)) (as amended by section  
10 3(b)) is amended to read as follows: “A food or dietary  
11 supplement for which a claim, subject to section  
12 403(r)(1)(B) and 403(r)(3) or section 403(r)(1)(B) and  
13 403(r)(5)(D), is made in accordance with the require-  
14 ments of section 403(r) is not a drug solely because the  
15 label or the labeling contains such a claim. A food, dietary  
16 ingredient, or dietary supplement for which a truthful and  
17 nonmisleading statement is made in accordance with sec-  
18 tion 403(r)(1) is not a drug solely because the label or  
19 the labeling contains such a statement.”.

20 (b) SECTION 403.—Section 403 (21 U.S.C. 343) is  
21 amended by adding at the end the following:  
22 “A dietary supplement shall not be deemed misbranded  
23 solely because its label or labeling contains directions or  
24 conditions of use or warnings.”.

1 **SEC. 8. ADMINISTRATIVE AND JUDICIAL REVIEW.**

2 The Federal Food, Drug, and Cosmetic Act is amend-  
3 ed by adding at the end of chapter III (21 U.S.C. 331  
4 et seq.) the following new section:

5 **“SEC. 311. WARNING LETTERS.**

6 “Any warning letter or similar written threat of en-  
7 forcement under the Federal Food, Drug, and Cosmetic  
8 Act constitutes final agency action for the purpose of ob-  
9 taining judicial review under chapter 7 of title 5, United  
10 States Code, if the matter with respect to such letter or  
11 threat is not resolved within 60 days from the date such  
12 letter or threat is delivered to any person subject to this  
13 Act. In any proceeding for judicial review of a warning  
14 letter or similar written threat of enforcement under the  
15 Act, the United States bears the burden of proof on each  
16 element of each alleged violation of law described.”.

17 **SEC. 9. WITHDRAWAL OF THE REGULATIONS AND NOTICE.**

18 (a) IN GENERAL.—The advance notice of proposed  
19 rulemaking concerning dietary supplements published in  
20 the Federal Register of June 18, 1993 (58 FR 33690–  
21 33700), the notices of proposed rulemaking concerning  
22 nutrition labeling for dietary supplements and nutrient  
23 content claims for dietary supplements published in the  
24 Federal Register of June 18, 1993 (58 FR 33715–33731  
25 and 58 FR 33731–33751), and the final rules and notices  
26 published in the Federal Register of January 4, 1994 con-

cerning nutrition labeling for dietary supplements and nutrient content claims for dietary supplements (59 FR 354–378 and 378–395) are null and void and of no force or effect insofar as they apply to dietary supplements. Final regulations and notices published in the Federal Register of January 4, 1994 concerning health claims for dietary supplements under the Nutrition Labeling and Education Act of 1990 (59 FR 395–426) shall not be affected by this section and shall remain in effect until 120 days after the date of the submission of the final report of the Commission established under section 11 to the President and to Congress, or 28 months after the date of enactment of this Act, whichever is earlier.

(b) NOTICE OF REVOCATION.—The Secretary of Health and Human Services shall publish notices in the Federal Register to revoke all of the items declared to be null and void and of no force or effect under subsection (a).

(c) ISSUANCE OF REGULATIONS.—Notwithstanding any provision of the Nutrition Labeling and Education Act of 1990—

(1) no regulation is required to be issued pursuant to such Act with respect to dietary supplements of vitamins, minerals, herbs, amino acids, or other similar nutritional substances; and

1           (2) no regulation that is issued in whole or in  
2           part pursuant to such Act shall have any force or ef-  
3           fect with respect to any dietary supplement of vita-  
4           mins, minerals, herbs, amino acids, or other similar  
5           nutritional substances unless such regulation is is-  
6           sued pursuant to rulemaking proceedings that are  
7           initiated by an advance notice of proposed rule-  
8           making that is published no earlier than 2 years  
9           after the date of enactment of this Act, and followed  
10          by, at least, a notice of proposed rulemaking prior  
11          to issuance of the final regulation, except insofar as  
12          the regulation authorizes the use of labeling about  
13          calcium, folic acid, or other matters and does not  
14          prohibit the use of any labeling.

15 **SEC. 10. DIETARY SUPPLEMENT INGREDIENT LABELING**  
16 **AND NUTRITION INFORMATION LABELING.**

17          (a) MISBRANDED SUPPLEMENTS.—Section 403 of  
18 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
19 343) is amended by adding at the end the following new  
20 paragraph:

21           “(s) If—

22                   “(1) it is a dietary supplement; and

23                   “(2)(A) the label or labeling of the supplement  
24           fails to list—



1           “(i) the name of each ingredient of the  
2           supplement that is described in section 201(ff);  
3           and

4           “(ii)(I) the quantity of each such ingredi-  
5           ent; or

6           “(II) with respect to a proprietary blend of  
7           such ingredients, the total quantity of all ingre-  
8           dients in the blend;

9           “(B) the label or labeling of the dietary supple-  
10          ment fails to identify the product by using the term  
11          ‘dietary supplement’, which term may be modified  
12          with the name of such an ingredient;

13          “(C) the supplement contains an ingredient de-  
14          scribed in section 201(ff) (1)(C), and the label or la-  
15          beling of the supplement fails to identify any part of  
16          the plant from which the ingredient is derived;

17          “(D) the supplement—

18                  “(i) is covered by the specifications of an  
19                  official compendium;

20                  “(ii) is represented as conforming to the  
21                  specifications of an official compendium; and

22                  “(iii) fails to so conform; or

23          “(E) the supplement—

24                  “(i) is not covered by the specifications of  
25                  an official compendium; and

1           “(ii)(I) fails to have the identity and  
2           strength that the supplement is represented to  
3           have; or

4           “(II) fails to meet the quality (including  
5           tablet or capsule disintegration), purity, or  
6           compositional specifications, based on validated  
7           assay or other appropriate methods, that the  
8           supplement is represented to meet.”.

9           (b) SUPPLEMENT LISTING ON NUTRITION LABEL-  
10          ING.—Section 403(q)(1) of the Federal Food, Drug, and  
11          Cosmetic Act (21 U.S.C. 343(q)(1)) is amended by adding  
12          at the end the following: “A dietary supplement may bear  
13          on the nutrition label or in labeling a listing and quantity  
14          of ingredients that have not been deemed essential nutri-  
15          ents by the Secretary if such ingredients are prominently  
16          identified as not having been shown to be essential or not  
17          having an established daily value.”.

18          (c) DIETARY SUPPLEMENT LABELING EXEMP-  
19          TIONS.—Section 403(q)(5) of the Federal Food, Drug,  
20          and Cosmetic Act (21 U.S.C. 343(q)(5)) is amended by  
21          adding at the end the following new clause:

22          “(H) The labels of dietary supplements shall not be  
23          required to bear the nutrition information under subpara-  
24          graph (1), but shall be required to list immediately above  
25          the ingredient listing the amount of nutrients required by

1 the Secretary to be listed pursuant to clause (C), (D) or  
 2 (E) of subparagraph (1) or clause (A) of subparagraph  
 3 (2) that are present in significant amounts in the supple-  
 4 ment.”.

5 (d) VITAMINS AND MINERALS.—Section 411(b)(2) of  
 6 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
 7 350(b)(2)) is amended—

8 (1) by striking “vitamins and minerals” and in-  
 9 serting “dietary supplement ingredients described in  
 10 section 201(ff)”;

11 (2) by striking “(2)(A)” and inserting “(2)”;  
 12 and

13 (3) by striking subparagraph (B).

14 **SEC. 11. COMMISSION ON DIETARY SUPPLEMENT LABELS.**

15 (a) ESTABLISHMENT.—There shall be established as  
 16 an independent agency within the executive branch a com-  
 17 mission to be known as the Commission on Dietary Sup-  
 18 plement Labels (hereafter in this section referred to as  
 19 the “Commission”).

20 (b) MEMBERSHIP.—

21 (1) COMPOSITION.—The Commission shall be  
 22 composed of 7 members who shall be appointed by  
 23 the President.

24 (2) EXPERTISE REQUIREMENT.—The members  
 25 of the Commission shall consist of individuals with

1 expertise and experience in dietary supplements and  
2 in the manufacture, regulation, distribution, and use  
3 of such supplements. At least three of the members  
4 of the Commission shall be qualified by scientific  
5 training and experience to evaluate the benefits to  
6 health of the use of dietary supplements and one of  
7 such three members shall have experience in phar-  
8 macognosy, medical botany, traditional herbal medi-  
9 cine, or other related sciences. No member of the  
10 Commission shall be biased against dietary supple-  
11 ments.

12 (c) FUNCTIONS OF THE COMMISSION.—The Commis-  
13 sion shall conduct a study on, and provide recommenda-  
14 tions for, the regulation of label claims for dietary supple-  
15 ments, including procedures for the evaluation of such  
16 claims. In making such recommendations, the Commission  
17 shall evaluate how best to provide truthful and  
18 nonmisleading information to consumers so that such con-  
19 sumers may make informed health care choices for them-  
20 selves and their families.

21 (d) REPORTS AND RECOMMENDATIONS.—

22 (1) FINAL REPORT REQUIRED.—Not later than  
23 24 months after the date of enactment of this Act,  
24 the Commission shall prepare and submit to the

1 President and to the Congress a final report on the  
2 study required by this section.

3 (2) RECOMMENDATIONS.—The report described  
4 in paragraph (1) shall contain such recommenda-  
5 tions, including recommendations for legislation, as  
6 the Commission deems appropriate.

7 (e) ADMINISTRATIVE POWERS OF THE COMMIS-  
8 SION.—

9 (1) HEARINGS.—The Commission may hold  
10 hearings, sit and act at such times and places, take  
11 such testimony, and receive such evidence as the  
12 Commission considers advisable to carry out the  
13 purposes of this section.

14 (2) INFORMATION FROM FEDERAL AGENCIES.—  
15 The Commission may secure directly from any Fed-  
16 eral department or agency such information as the  
17 Commission considers necessary to carry out the  
18 provisions of this section.

19 (3) AUTHORIZATION OF APPROPRIATIONS.—  
20 There are authorized to be appropriated such sums  
21 as may necessary to carry out the provisions of this  
22 section.

1 **SEC. 12. GOOD MANUFACTURING PRACTICES.**

2 Section 402 of the Federal Food, Drug, and Cosmetic  
3 Act (21 U.S.C. 342) (as amended by section 4) is further  
4 amended by adding at the end the following:

5 “(g)(1) If it is a dietary supplement and it has been  
6 prepared, packed, or held under conditions that do not  
7 meet current good manufacturing practice regulations is-  
8 sued by the Secretary under subparagraph (2).

9 “(2) The Secretary may by regulation prescribe good  
10 manufacturing practices for dietary supplements. Such  
11 regulations shall be modeled after current good manufac-  
12 turing practice regulations for food and may not impose  
13 standards for which there is no current and generally  
14 available analytical methodology. No standard of current  
15 good manufacturing practice may be imposed unless such  
16 standard is included in a regulation promulgated after no-  
17 tice and opportunity for comment in accordance with the  
18 Administrative Procedure Act.”.

19 **SEC. 13. OFFICE OF DIETARY SUPPLEMENTS.**

20 (a) IN GENERAL.—Title IV of the Public Health  
21 Service Act is amended by inserting after section 486 (42  
22 U.S.C. 287c–3) the following:

1 “Subpart 4—Office of Dietary Supplements

2 **“SEC. 486E. DIETARY SUPPLEMENTS.**

3 “(a) ESTABLISHMENT.—The Secretary shall estab-  
4 lish an Office of Dietary Supplements within the National  
5 Institutes of Health.

6 “(b) PURPOSE.—The purposes of the Office are—

7 “(1) to explore more fully the potential role of  
8 dietary supplements as a significant part of the ef-  
9 forts of the United States to improve health care;  
10 and

11 “(2) to promote scientific study of the benefits  
12 of dietary supplements in maintaining health and  
13 preventing chronic disease and other health-related  
14 conditions.

15 “(c) DUTIES.—The Director of the Office of Dietary  
16 Supplements shall—

17 “(1) conduct and coordinate scientific research  
18 within the National Institutes of Health relating to  
19 dietary supplements and the extent to which the use  
20 of dietary supplements can limit or reduce the risk  
21 of diseases such as heart disease, cancer, birth de-  
22 fects, osteoporosis, cataracts, or prostatism;

23 “(2) collect and compile the results of scientific  
24 research relating to dietary supplements, including

1 scientific data from foreign sources or the Office of  
2 Alternative Medical Practice;

3 “(3) serve as the principal advisor to the Sec-  
4 retary and to the Assistant Secretary for Health,  
5 and to provide advice to the Director of the National  
6 Institutes of Health, the Director of the Centers for  
7 Disease Control and Prevention, and the Commis-  
8 sioner of Food and Drugs, on issues relating to die-  
9 tary supplements including—

10 “(A) dietary intake regulations;

11 “(B) the safety of dietary supplements;

12 “(C) claims characterizing the relationship  
13 between—

14 “(i) dietary supplements; and

15 “(ii) (I) prevention of disease or other  
16 health-related conditions; and

17 “(II) maintenance of health; and

18 “(D) scientific issues arising in connection  
19 with the labeling and composition of dietary  
20 supplements;

21 “(4) compile a database of scientific research  
22 on dietary supplements and individual nutrients; and

23 “(5) coordinate funding relating to dietary sup-  
24 plements for the National Institutes of Health.



1       “(d) DEFINITION.—As used in this section, the term  
 2 ‘dietary supplement’ has the meaning given the term in  
 3 section 201(ff) of the Federal Food, Drug, and Cosmetic  
 4 Act (21 U.S.C. 321(ff)).

5       “(e) AUTHORIZATION OF APPROPRIATIONS.—There  
 6 are authorized to be appropriated to carry out this section  
 7 \$5,000,000 for fiscal year 1994 and such sums as may  
 8 be necessary for each subsequent fiscal year.”.

9       (b) CONFORMING AMENDMENT.—Section 401(b)(2)  
 10 of the Public Health Service Act (42 U.S.C. 281(b)(2))  
 11 is amended by adding at the end the following:

12               “(E) The Office of Dietary Supplements.”.

Passed the Senate August 13 (legislative day, August 11), 1994.

Attest:

MARTHA S. POPE,  
*Secretary.*

S 784 RFH——2

S 784 RFH——3